Is Madrigal Pharmaceuticals, Inc. (MDGL) a Buy, Sell, or Hold?
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$536.86 USD
$5.86 (1.1%)
- Volume
- 241.71K
- Average Volume
- 328.03K
- Market Capitalization
- $12.38B
- P/E Ratio
- -41.94
- Dividend Yield
- 0.00%
- Price Target
- $649.00
- Year High
- $615.00
- Year Low
- $286.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.50
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | William J. Sibold |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MDGL |
| CUSIP | 558868105 |
| CIK | 0001157601 |
| Web | https://www.madrigalpharma.com |
| Phone | 267 824 2827 |
| Currency | USD |
| Employees | 915 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.64 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.50 |
| Quick Ratio | 3.16 |
| Cash Ratio | 0.69 |
Sales & Book Value
| Annual Sales | $958.4M |
| Price / Sales | 10.93 |
| Cash Flow | -9.38 |
| Price / Cash Flow | -45.44 |
| Price / Book | 28.68 |
Price Target and Rating
| Average Stock Price Forecast | $649.00 |
| High Stock Price Forecast | $964.00 |
| Low Stock Price Forecast | $542.00 |
| Forecast Upside/Downside | -17.28% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 23 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-12.85 |
| Trailing P/E Ratio | -41.94 |
| PEG Ratio | -1.43 |
| P/E Growth | -1.43 |
| Net Income | $-288.28M |
| Net Margin | -27.32% |
| Pretax Margin | -27.32% |
| Return on Equity | -50.15% |
| Return on Assets | -25.21% |
Financials Score
| AltmanZ Score | 9.36 |
| Piotroski Score | 2.00 |
| Working Capital | 844.05M |
| Total Assets | 1.23B |
| Ebit | -282.61M |
| Market Cap | 12.38B |
| Total Liabilities | 683.87M |
Poll Results
About Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania. ...
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
2026-07-13 08:00:00
Received two new U.S. Rezdiffra ® (resmetirom) patents in F2/F3; both patents will be listed in the FDA's Orange Book Received new U.S. resmetirom patent directed to a method of administering resmetirom to treat well-compensated cirrhosis (F4c) CONSHOHOCKEN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the United States Patent and Trademark Office (USPTO) issued three new resmetirom patents.
3 Under-the-Radar Stocks to Buy and Hold
2026-07-10 14:30:00
These three biotechs are posting strong revenue growth. Brand-new launches and label expansions should help them improve their lineups.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-07-06 16:05:00
CONSHOHOCKEN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2026 to seven new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
2026-07-02 02:27:00
/PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK) y su filial Ribocure Pharmaceuticals AB (en adelante, "Ribo"), en colaboración con Madrigal
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
2026-07-01 21:19:00
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce the successful achievement of the first candidate drug nomination milestone within their siRNA partnership.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-06-22 16:05:00
CONSHOHOCKEN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2026 to five new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
3 Under-the-Radar Stocks to Buy and Hold for a Decade
2026-06-16 03:30:00
All three could become highly prominent biotech companies within 10 years.
2026-06-10 14:22:23
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Madrigal Pharmaceuticals, Inc. (MDGL) stock price?
-
Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) stock price is $536.86 in the last trading session. During the trading session, MDGL stock reached the peak price of $615 while $286.44 was the lowest point it dropped to. The percentage change in MDGL stock occurred in the recent session was 1.1% while the dollar amount for the price change in MDGL stock was $5.86.
-
MDGL's industry and sector of operation?
-
The NASDAQ listed MDGL is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MDGL?
-
Rita Thakkar | Senior VP & Chief Accounting Officer
William J. Sibold | Chief Executive Officer, President & Director
Tina E. Ventura | Chief Investor Relations Officer
Mardi C. Dier | Executive Vice President & Chief Financial Officer
Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary -
How many employees does MDGL have?
-
Number of MDGL employees currently stands at 915. MDGL operates from Four Tower Bridge, West Conshohocken, PA 19428, US.
-
Link for MDGL official website?
-
Official Website of MDGL is: https://www.madrigalpharma.com
-
How do I contact MDGL?
-
MDGL could be contacted at phone #267 824 2827 and can also be accessed through its website. MDGL operates from Four Tower Bridge, West Conshohocken, PA 19428, US.
-
How many shares of MDGL are traded daily?
-
The average number of MDGL shares traded daily for last 3 months was 328.03K.
-
What is the market cap of MDGL currently?
-
The market value of MDGL currently stands at $12.38B with its latest stock price at $536.86